Loopdx Opens €1 Million Round to Bring its Sepsis Biomarker to Market

Loopdx is looking for capital. The Catalan company has opened a $1.06 million (€1 million) round aimed at financing the market launch of its exclusive biomarker for sepsis, Eduard Guerrero, the company’s head of accounts, has confirmed to PlantaDoce. The startup expects the process to close in September, as several funds, whose names have not been disclosed, have already agreed to participate.

The Catalan company estimates that the biomarker they have designed will reach the market in early 2023. Since its creation in 2018, Loopdx has raised $719.000 (€680,000) from public funding. The latest was the venture capital fund sponsored by the Center for Industrial Technological Development (Cdti), Neotec, endowed with $265,000 (€250,000), granted this past month.

In this area, the company is also waiting to receive another $1.16 million (€1.1 million) from the Cdti, although this aid is still in the provisional resolution proposal stage.

Read more about Loopdx and find the latest business headlines of the day with teh Born2Invest mobile app.

Loopdx has on the horizon to enter the hospital market, both on a public scale and in private centers

Currently, the sepsis diagnostics market has two biomarkers. The first is the blood culture system, which detects the condition in the bloodstream within one to two days. The other system is procalcitonin, which only works during the severe phase of sepsis.

Loopdx believes that its biomarker has “a new potential to detect the state of infection in the blood three hours after the bacteria enter the bloodstream,” according to Guerrero. The company’s objective is to enter the hospital market, both on a public scale and in private centers, although the startup assures that it will be easier to work in the latter.

The prototype is finished, but the biomarker must pass the regulatory phase. Loopdx is conducting trials in collaboration with two Catalan hospitals, whose names have not been disclosed. The company’s intention is to start sales in Spain, where the network has already been set up.

After its first steps, Loopdx received $31,750 (€30,000) from a U.S. accelerator

After its first steps, Loopdx received $31,750 (€30,000) from a U.S. business accelerator, whose name has not been disclosed, and a further $10,580 (€10,000) from the municipal agency Barcelona Activa.

The company currently has six employees. In Spain, 17,000 people die every year from different types of septicemia. This condition is one of the most serious diseases in the health system, since 6% of patients enter with an infectious pathology and, of these, one in twenty suffers from sepsis.

__

(Featured image by Belova59 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.